ADMA
ADMA Biologics, Inc.19.17
-0.56-2.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
4.57BP/E (TTM)
22.29Basic EPS (TTM)
0.86Dividend Yield
0%Recent Filings
8-K
ADMA refutes short seller
ADMA Biologics fired back at Culper Research's March 24 short report, refuting claims of channel stuffing and weak ASCENIV demand. Distributor data shows ASCENIV end-user demand rising over two years, with inventory at 90 days on hand as of March 22, 2026—industry standard. Clean audits confirm controls. Demand pulls strong.
8-K
ADMA starts $125M ASR
ADMA Biologics launched a $125 million accelerated share repurchase with JPMorgan on March 2, 2026, part of its $500 million program and $200 million 2026 target. It pays upfront and gets ~6.4 million shares initially on March 3, based on $15.57 closing price, with settlement in five months. Stock undervalued. Final shares hinge on VWAP.
8-K
CFO retires; Kohler promoted
ADMA Biologics announced CFO Brad Tade's retirement effective February 25, 2026, post-10-K filing, transitioning to consultant through July 31 at $41,666.67 monthly. Terry Kohler, ex-CFO of OptiNose and Verrica with deep pharma finance experience, steps in February 26 as new CFO with $500k base and 45% target bonus. Smooth handoff preserves continuity amid record 2025 results.
10-K
FY2025 results
ADMA Biologics drove FY2025 revenue to $510M, up 20% y/y, with ASCENIV surging 51% to $363M on expanding prescriber base and real-world data, while BIVIGAM dipped 14% amid voluntary Q2-Q3 withdrawals (resolved). Q4 momentum accelerated via FDA-approved yield enhancement boosting IG output 20%+ from same plasma, lifting gross margins to 57% from 51%. Boca Facility expansions and plasma center divestiture (three sites for $12M, long-term supply secured) enhance efficiency. Debt refinanced to $300M JPM facility at ~6.4%. Yet supply disruptions from geopolitics loom.
8-K
ADMA hits $510M revenue
ADMA Biologics reported preliminary FY 2025 unaudited revenue of $510-511 million, hitting guidance, with year-end cash at $88 million and Q4 operating cash flow near $40 million. Yield-enhanced production scales up in 2026 for margin gains, while divesting three plasma centers for $12 million bolsters supply deals and cuts costs. Revenue jumps to $635 million in 2026. Cash fuels growth.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ARTV
Artiva Biotherapeutics, Inc.
4.55-1.75
BIVI
BioVie Inc.
1.43+0.00
HCWB
HCW Biologics Inc.
1.78-0.09
IMTX
Immatics N.V.
10.09+0.11
IVBXF
Innovent Biologics Inc.
10.55+0.00
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SMMT
Summit Therapeutics Inc.
17.23-0.15
XBIT
XBiotech Inc.
2.45-0.08
ZIVO
Zivo Bioscience, Inc.
9.00+0.00